{"id":43180,"date":"2025-10-13T17:30:03","date_gmt":"2025-10-13T09:30:03","guid":{"rendered":"https:\/\/flcube.com\/?p=43180"},"modified":"2025-10-13T17:30:04","modified_gmt":"2025-10-13T09:30:04","slug":"sino-biopharma-subsidiary-secures-breakthrough-therapy-designation-for-tqb2102-adc-targeting-her2%e2%80%91positive-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43180","title":{"rendered":"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer"},"content":{"rendered":"\n<p><strong>Jiangsu Chia Tai\u202f Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ)<\/strong>, a wholly\u2011owned subsidiary of China\u2011listed Sino Biopharmaceutical Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), announced today that the U.S. Food and Drug Administration (FDA) has granted <strong>Breakthrough Therapy Designation<\/strong> to its bispecific antibody\u2011drug conjugate (ADC) <strong>TQB2102 for Injection<\/strong>. The designation applies to patients with <strong>HER2 IHC\u202f3+ advanced colorectal cancer<\/strong> who have progressed after standard platinum\u2011based chemotherapy (oxaliplatin, irinotecan) and fluoropyrimidine regimens. TQB2102 has now entered the Breakthrough Therapy program for a second time, following a July 2025 designation for HER2\u2011positive breast cancer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>TQB2102 (bispecific ADC)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>HER2 IHC\u202f3+ advanced colorectal cancer, post\u2011oxaliplatin\/irinotecan\/fluoropyrimidine<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>FDA Breakthrough Therapy<\/td><\/tr><tr><td><strong>Previous Breakthrough<\/strong><\/td><td>HER2\u2011positive breast cancer (July\u202f2025)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Dual\u2011epitope targeting (ECD2\u202f+\u202fECD4) via trastuzumab\u2011 and pertuzumab\u2011derived bispecific antibody<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-overview\">Product Overview<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bispecific Design<\/strong> \u2013 TQB2102 combines the antigen\u2011binding domains of <strong>trastuzumab<\/strong> and <strong>pertuzumab<\/strong> into a single antibody scaffold, enabling simultaneous engagement of two non\u2011overlapping HER2 epitopes (ECD2 &amp; ECD4).<\/li>\n\n\n\n<li><strong>ADC Payload<\/strong> \u2013 Conjugated to a potent cytotoxic payload that is released intracellularly upon HER2\u2011mediated internalization, maximizing tumor cell killing while sparing normal tissue.<\/li>\n\n\n\n<li><strong>Clinical Advantage<\/strong> \u2013 Preclinical models demonstrate a ~4\u2011fold increase in tumor\u2011cell cytotoxicity versus monospecific HER2 ADCs, attributable to enhanced avidity and cross\u2011linking of HER2 receptors.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-context\">Clinical Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER2\u2011Positive Colorectal Cancer<\/strong> \u2013 A rare but aggressive subset (~2\u20133\u202f% of CRC cases) with limited therapeutic options after failure of first\u2011line chemotherapy.<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong> \u2013 Existing HER2\u2011targeted therapies (e.g., trastuzumab, pertuzumab) have modest efficacy in CRC; TQB2102\u2019s bispecific architecture offers a novel mechanism to overcome resistance.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Development<\/strong> \u2013 Breakthrough Therapy designation unlocks priority review, rolling submissions, and potential for expedited FDA review, shortening time to market.<\/li>\n\n\n\n<li><strong>Portfolio Expansion<\/strong> \u2013 Adds a second indication to TQB2102\u2019s pipeline, reinforcing CTTQ\u2019s focus on HER2\u2011targeted oncology therapeutics.<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong> \u2013 With an estimated global market of >\u202f$10\u202fbillion for HER2\u2011positive solid tumors, TQB2102 could capture a sizable share of the colorectal cancer segment.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-sino-biopharma-amp-cttq\">About Sino\u202fBiopharma &amp; CTTQ<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sino\u202fBiopharma Ltd.<\/strong> (HKG:\u202f1177) is a leading Chinese biopharmaceutical company engaged in the discovery, development, and commercialization of innovative oncology and immunology products.<\/li>\n\n\n\n<li><strong>CTTQ<\/strong> is a wholly\u2011owned subsidiary specializing in antibody\u2011drug conjugate development, with a robust pipeline of bispecific ADC candidates across multiple tumor types.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Chia Tai\u202f Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a wholly\u2011owned subsidiary of China\u2011listed Sino Biopharmaceutical Ltd&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":43181,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,16,661,83,908,313],"class_list":["post-43180","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-cancer","tag-chia-tai-tianqing-pharmaceutical","tag-her2","tag-hkg-1177","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Chia Tai\u202f Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a wholly\u2011owned subsidiary of China\u2011listed Sino Biopharmaceutical Ltd. (HKG: 1177), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its bispecific antibody\u2011drug conjugate (ADC) TQB2102 for Injection. The designation applies to patients with HER2 IHC\u202f3+ advanced colorectal cancer who have progressed after standard platinum\u2011based chemotherapy (oxaliplatin, irinotecan) and fluoropyrimidine regimens. TQB2102 has now entered the Breakthrough Therapy program for a second time, following a July 2025 designation for HER2\u2011positive breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43180\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Chia Tai\u202f Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a wholly\u2011owned subsidiary of China\u2011listed Sino Biopharmaceutical Ltd. (HKG: 1177), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its bispecific antibody\u2011drug conjugate (ADC) TQB2102 for Injection. The designation applies to patients with HER2 IHC\u202f3+ advanced colorectal cancer who have progressed after standard platinum\u2011based chemotherapy (oxaliplatin, irinotecan) and fluoropyrimidine regimens. TQB2102 has now entered the Breakthrough Therapy program for a second time, following a July 2025 designation for HER2\u2011positive breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43180\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-13T09:30:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T09:30:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1308.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer\",\"datePublished\":\"2025-10-13T09:30:03+00:00\",\"dateModified\":\"2025-10-13T09:30:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180\"},\"wordCount\":400,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1308.webp\",\"keywords\":[\"Breakthrough therapy\",\"Cancer\",\"Chia Tai Tianqing Pharmaceutical\",\"HER2\",\"HKG: 1177\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43180#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43180\",\"name\":\"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1308.webp\",\"datePublished\":\"2025-10-13T09:30:03+00:00\",\"dateModified\":\"2025-10-13T09:30:04+00:00\",\"description\":\"Jiangsu Chia Tai\u202f Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a wholly\u2011owned subsidiary of China\u2011listed Sino Biopharmaceutical Ltd. (HKG: 1177), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its bispecific antibody\u2011drug conjugate (ADC) TQB2102 for Injection. The designation applies to patients with HER2 IHC\u202f3+ advanced colorectal cancer who have progressed after standard platinum\u2011based chemotherapy (oxaliplatin, irinotecan) and fluoropyrimidine regimens. TQB2102 has now entered the Breakthrough Therapy program for a second time, following a July 2025 designation for HER2\u2011positive breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43180\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1308.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1308.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43180#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Chia Tai\u202f Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a wholly\u2011owned subsidiary of China\u2011listed Sino Biopharmaceutical Ltd. (HKG: 1177), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its bispecific antibody\u2011drug conjugate (ADC) TQB2102 for Injection. The designation applies to patients with HER2 IHC\u202f3+ advanced colorectal cancer who have progressed after standard platinum\u2011based chemotherapy (oxaliplatin, irinotecan) and fluoropyrimidine regimens. TQB2102 has now entered the Breakthrough Therapy program for a second time, following a July 2025 designation for HER2\u2011positive breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43180","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer","og_description":"Jiangsu Chia Tai\u202f Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a wholly\u2011owned subsidiary of China\u2011listed Sino Biopharmaceutical Ltd. (HKG: 1177), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its bispecific antibody\u2011drug conjugate (ADC) TQB2102 for Injection. The designation applies to patients with HER2 IHC\u202f3+ advanced colorectal cancer who have progressed after standard platinum\u2011based chemotherapy (oxaliplatin, irinotecan) and fluoropyrimidine regimens. TQB2102 has now entered the Breakthrough Therapy program for a second time, following a July 2025 designation for HER2\u2011positive breast cancer.","og_url":"https:\/\/flcube.com\/?p=43180","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-13T09:30:03+00:00","article_modified_time":"2025-10-13T09:30:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1308.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43180#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43180"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer","datePublished":"2025-10-13T09:30:03+00:00","dateModified":"2025-10-13T09:30:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43180"},"wordCount":400,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43180#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1308.webp","keywords":["Breakthrough therapy","Cancer","Chia Tai Tianqing Pharmaceutical","HER2","HKG: 1177","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43180#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43180","url":"https:\/\/flcube.com\/?p=43180","name":"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43180#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43180#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1308.webp","datePublished":"2025-10-13T09:30:03+00:00","dateModified":"2025-10-13T09:30:04+00:00","description":"Jiangsu Chia Tai\u202f Tianqing Pharmaceutical Co.,\u202fLtd. (CTTQ), a wholly\u2011owned subsidiary of China\u2011listed Sino Biopharmaceutical Ltd. (HKG: 1177), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its bispecific antibody\u2011drug conjugate (ADC) TQB2102 for Injection. The designation applies to patients with HER2 IHC\u202f3+ advanced colorectal cancer who have progressed after standard platinum\u2011based chemotherapy (oxaliplatin, irinotecan) and fluoropyrimidine regimens. TQB2102 has now entered the Breakthrough Therapy program for a second time, following a July 2025 designation for HER2\u2011positive breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43180#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43180"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43180#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1308.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1308.webp","width":1080,"height":608,"caption":"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43180#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2\u2011Positive Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1308.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43180"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43180\/revisions"}],"predecessor-version":[{"id":43182,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43180\/revisions\/43182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43181"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}